SQUAWK/NEWS
Account
Theme
Account
Menu
Live NewsCategoriesequity

Xencor, Inc. (XNCR) News

Follow Xencor, Inc. (XNCR) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 17 public stories across 12 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.

Symbol XNCR Asset equity Sector Markets 90 days 12 Last 34.04 Updated Nov 04, 2026, 10:54 PM UTC Open live news feed Open XNCR chart & news
M Xencor Q3 Revenue Tops Estimates on Alexion Royalty Contribution Xencor's Q3 revenue exceeded estimates, with an Alexion royalty contribution. EQUITY | Nov 04, 2026, 10:54 PM UTC M Xencor Reports Q3 Revenue of $116.5 Million, Net Income of $39.4 Million Xencor reported diluted earnings of $0.50 per share. Revenue was $21.0 million and net income was a loss of $6.0 million in the year-earlier quarter. EQUITY | Nov 04, 2026, 09:05 PM UTC M Xencor Reports Third-Quarter 2026 Financial Results Xencor updated results for XmAb819 in advanced clear cell renal cell carcinoma. EQUITY | Nov 04, 2026, 09:02 PM UTC M Xencor Shares Rise 33% After Early-Stage Kidney Cancer Trial Data Xencor said its treatment for certain forms of kidney cancer showed “impressive antitumor activity” in a recent early-stage trial. Shares rose 33% to $33.56 in premarket trading Monday. EQUITY | Oct 26, 2026, 10:47 AM UTC L Xencor Price Target Raised to $29.00/Share From $27.00 by Truist Securities Ratings actions from Benzinga NEWS | Sep 28, 2026, 03:29 PM UTC L Truist Securities reiterates Buy rating on Xencor, $29 price target Truist Securities reiterated their Buy rating on Xencor's stock with a price target of $29.00.The price target implies an upside of 21.8% from the Sep 25 close of $23.80.Key takeaways from the analyst noteEncouraging Cli EQUITY | Sep 28, 2026, 03:18 PM UTC L XNCR late-stage T-cell engager programs advance; pivotal data eyed soon Session coverage says XNCR is moving its T-cell engager and immunology programs into late-stage development, with pivotal readouts expected at ESMO and in phase II-B UC studies. EQUITY | Sep 09, 2026, 04:21 PM UTC L XNCR flags strategic shift to proprietary late-stage XmAb RCC development Company discussion points to a strategic shift toward late-stage development of proprietary XmAb molecules, citing pivotal RCC data for an ENPP3 T-cell engager and expected ESMO timing. EQUITY | Sep 09, 2026, 03:49 PM UTC L JP Morgan lifts Xencor price target to $21 from $14 JP Morgan raised its Xencor price target to $21.00 per share from $14.00, while maintaining the stock at Neutral, per TradingView News via Benzinga. EQUITY | Sep 03, 2026, 09:20 PM UTC L XNCR - Xencor to Present at the 2026 Cantor Global Healthcare Conference XNCR - Xencor to Present at the 2026 Cantor Global Healthcare Conference EQUITY | Sep 02, 2026, 08:04 PM UTC L Xencor management set to present at Cantor Global Healthcare Conference Xencor, Inc. (NASDAQ:XNCR) said management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EQUITY | Sep 02, 2026, 08:01 PM UTC L Raymond James raises Xencor price target to $46 from $40 Raymond James raised its Xencor price target to $46.00 per share from $40.00 and maintained a Strong Buy rating, per TradingView News via Benzinga. EQUITY | Sep 01, 2026, 03:53 PM UTC L XNCR - Xencor Reports Second Quarter 2026 Financial Results XNCR - Xencor Reports Second Quarter 2026 Financial Results EARNINGS | Aug 05, 2026, 08:04 PM UTC H WBLR Updates Analyst Conviction List Adds and removes stocks from conviction list EQUITY | Aug 03, 2026, 11:59 AM UTC H Xencor to receive $105M from Alexion Xencor gets $105M from Alexion EQUITY | Jul 29, 2026, 08:02 PM UTC L XNCR Xencor announces proffered Paper oral presentation at esmo 2026 for phase 1 clinical study of xmab819 in advanced clear cell renal cell XNCR Xencor announces proffered Paper oral presentation at esmo 2026 for phase 1 clinical study of xmab819 in advanced clear cell renal cell carcinoma EQUITY | Jul 17, 2026, 01:11 PM UTC H Xencor price target lowered to $27 from $29 at Truist Truist lowered the firm's price target on Xencor to $27 from $29 and keeps a Buy rating on the shares as part of a broader research note updating the firm's models and previewing Q2 earnings in Biotech. The firm is antic EARNINGS | Jul 07, 2026, 01:15 PM UTC